Athenex Inc.'s (ATNX) shares more than halved in value on Monday morning after the biopharmaceutical company received a completed response letter from FDA regarding its oral paclitaxel plus encequidar for the treatment of metastatic breast cancer.
ATNX is currently trading at $5.77, down $6.33 or 52.28%, on the Nasdaq.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com